ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Cytokinetics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CYTK

Core Points - Rosen Law Firm is reminding purchasers of Cytokinetics, Inc. common stock from December 27, 2023, to May 6, 2025, about the lead plaintiff deadline on November 17, 2025 [1] - Investors who purchased Cytokinetics stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed against Cytokinetics regarding misleading statements about the New Drug Application for aficamten [5] Company Information - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the FDA approval of aficamten, specifically indicating an expected approval in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [5] - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for securities class action settlements in 2017 [4]